The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
11125
Understanding Zymfentra: The First and Only Subcutaneous Infliximab Offering a New Therapeutic Approach in CD and UC Maintenance
Date
May 21, 2024
Society: DDW
Zymfentra, the first and only subcutaneous infliximab approved by the FDA, now approved for CD and UC.
Sponsored by Celltrion Healthcare Co., LTD
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
The pancreas is composed of the epithelial and mesenchymal cells. Interaction between the two lineages guides proper formation of the pancreas and modulates progression of pancreatic diseases such as cancer…
Colorectal cancer (CRC) shows a dramatic drop in the five-year survival rate from 90% for localized tumors to 14% for metastatic CRC (mCRC). Our lab has identified LIN28B, an RNA-binding protein overexpressed in 30% of CRCs, as an oncogene that promotes CRC metastasis…
BACKGROUND: Siewert's topographic classification (SW) has been used for treatment plan of esophagogastric junction adenocarcinomas (EGJA). But recently, molecular classifications categorized EGJA with similar characteristics and prognosis…